ENCLAI Daily · Article of the day 19 Nov 2026 · ENCLAI Editorial

CSCO and ASCO recommend PD-1 inhibitors with chemotherapy for recurrent nasopharyngeal carcinoma

NEW MEDICAL STUDY · GUIDELINE · 19 NOVEMBER 2026CSCO and ASCO recommend PD-1 inhibitorswith chemotherapy for recurrentnasopharyngeal carcinomaPubMed 43008245GuidelineStudy typeJournal of clinicaloncologyjournal10 Nov 2026published**The CSCO and ASCO joint guideline recommends platinum-basedchemotherapy plus a programmed cell death protein 1 (PD-1)inhibitor as preferred first-line therapy for medically fitpatients with recurrent or metastatic nasopharyngeal carcinoma.What the study found1Evidence supports platinum-based chemotherapy combined with a PD-1inhibitor as the preferred first-line treatment for appropriatepatients.2Chemotherapy alone may be offered when immunotherapy is unsuitable ordeclined by the patient.3After achieving disease control, maintenance PD-1 inhibition should becontinued for up to two years.Who it applies toThe recommendations apply to patientswith recurrent and/or metastaticnasopharyngeal carcinoma who aremedically fit for systemic therapy.What it does not establishTreatment selection depends on priortherapy, disease extent, patientfitness, resource availability, localdrug approvals, and patientpreferences.The authors' conclusion“**The CSCO and ASCO joint guideline recommends platinum-basedchemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor aspreferred first-line therapy for medically fit patients with recurrentor metastatic nasopharyngeal carcinoma.”Summary of the published abstract, not medical advice. Read the paper before acting on it.Source: PubMed 43008245 · enclai.net/newsVerify every figure against the source before use; ENCLAI does not guarantee accuracy orcompleteness.
  1. **The CSCO and ASCO joint guideline recommends platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients with recurrent or metastatic nasopharyngeal carcinoma.
  2. Evidence supports platinum-based chemotherapy combined with a PD-1 inhibitor as the preferred first-line treatment for appropriate patients.
  3. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined by the patient.
  4. After achieving disease control, maintenance PD-1 inhibition should be continued for up to two years.
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

**The CSCO and ASCO joint guideline recommends platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients with recurrent or metastatic nasopharyngeal carcinoma. Maintenance PD-1 inhibition for up to two years is advised after disease control, while salvage surgery or re-irradiation is recommended for isolated locoregional recurrence.**

Who the findings apply to

The recommendations apply to patients with recurrent and/or metastatic nasopharyngeal carcinoma who are medically fit for systemic therapy.

Why this matters

This guideline synthesizes evidence from randomized trials, meta-analyses, and clinical experience to standardize treatment approaches for recurrent and metastatic nasopharyngeal carcinoma. It addresses first-line systemic therapy, maintenance strategies, locoregional consolidation, and salvage options based on efficacy, safety, and patient-centered outcomes.

What the study found

Evidence supports platinum-based chemotherapy combined with a PD-1 inhibitor as the preferred first-line treatment for appropriate patients. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined by the patient.

After achieving disease control, maintenance PD-1 inhibition should be continued for up to two years. Selected responders to first-line chemotherapy may also receive oral maintenance chemotherapy or locoregional consolidation intensity-modulated radiotherapy.

For patients with isolated locoregional recurrence amenable to local therapy, salvage surgery and re-irradiation are recommended options. Subsequent-line treatments include chemotherapy, PD-1 inhibitors, and antibody-drug conjugates.

What the result does not establish

Treatment selection depends on prior therapy, disease extent, patient fitness, resource availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care should accompany active anticancer treatment for advanced, incurable disease where available.

Authors’ conclusion

“Treatment should be individualized according to disease setting, prior therapy, expected toxicities, availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care, where available, should accompany active anticancer treatment for advanced, incurable disease.Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer.”

Study and sources

Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline

Guidelines & recommendations · Journal of clinical oncology · 2026-11-10

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.